Journal ArticleDOI
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
William J. Sandborn,Brian G. Feagan,Colleen Marano,Hongyan Zhang,Richard Strauss,Jewel Johanns,Omoniyi J. Adedokun,Cynthia Guzzo,Jean-Frederic Colombel,Jean-Frederic Colombel,Walter Reinisch,Peter R. Gibson,Judith Collins,Gunnar Järnerot,Paul Rutgeerts +14 more
Reads0
Chats0
TLDR
Golimumab (50 mg or 100 mg) maintained clinical response through week 54 in patients who responded to induction therapy with golimumab and had moderate-to-severe active ulcerative colitis; patients who received 100 mg Golimumab had clinical remission and mucosal healing at weeks 30 and 54.About:
This article is published in Gastroenterology.The article was published on 2014-01-01. It has received 595 citations till now. The article focuses on the topics: Golimumab & Maintenance therapy.read more
Citations
More filters
Journal ArticleDOI
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
Laurent Peyrin-Biroulet,William J. Sandborn,Bruce E. Sands,Walter Reinisch,Walter Reinisch,Willem A. Bemelman,Robert V Bryant,G R D’Haens,Iris Dotan,Marla Dubinsky,Brian G. Feagan,Gionata Fiorino,Richard B. Gearry,S. Krishnareddy,Peter L. Lakatos,Edward V. Loftus,P. Marteau,Pia Munkholm,Travis B. Murdoch,Ingrid Ordás,Remo Panaccione,Robert H. Riddell,J. Ruel,David T. Rubin,Mark A Samaan,Corey A. Siegel,Mark S. Silverberg,Jaap Stoker,Stefan Schreiber,Simon Travis,G. Van Assche,G. Van Assche,Silvio Danese,Julián Panés,Guillaume Bouguen,Sarah O’Donnell,Benjamin Pariente,S. Winer,Stephen B. Hanauer,J.-F. Colombel +39 more
TL;DR: Evidence- and consensus-based recommendations for selecting the goals for treat-to-target strategies in patients with IBD are made available and future studies are needed to determine how these targets will change disease course and patients’ quality of life.
Journal ArticleDOI
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management
Axel Dignass,James O. Lindsay,Andreas Sturm,Alastair Windsor,Jean-Frederic Colombel,Mathieu Allez,G. D'Haens,André D'Hoore,Gerassimos J. Mantzaris,Gottfried Novacek,Tom Øresland,Walter Reinisch,Miquel Sans,Eduard F. Stange,Severine Vermeire,Simon Travis,Gert Van Assche +16 more
TL;DR: The most widely used index for severe UC remains that of Truelove and Witts3: any patient who has a bloody stool frequency ≥ 6/day and a tachycardia (> 90 bpm), or temperature > 37.8 °C, or anaemia (haemoglobin 30 mm/h) has severe ulcerative colitis (Table 1.3) as mentioned in this paper.
Journal ArticleDOI
Current and emerging therapeutic targets for IBD
TL;DR: This Review aims to provide a comprehensive overview about current and future therapeutic approaches for IBD therapy and potential mechanisms of action of these therapeutic approaches and their implications for clinical therapy in IBD are discussed.
Journal ArticleDOI
The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy
Geoffrey C. Nguyen,Cynthia H. Seow,Cynthia Maxwell,Vivian Huang,Yvette Leung,Jennifer Jones,Grigorios I. Leontiadis,Frances Tse,Uma Mahadevan,C. Janneke van der Woude,Alain Bitton,Brian Bressler,Sharyle Fowler,John Marshall,Carrie Palatnick,Anna Pupco,Joel G. Ray,Laura E. Targownik,Janneke van der Woude,William G. Paterson +19 more
TL;DR: Optimal management of IBD before and during pregnancy is essential to achieving favorable maternal and neonatal outcomes.
Journal ArticleDOI
Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus
Brian Bressler,John Marshall,Charles N. Bernstein,Alain Bitton,Jennifer Jones,Grigorios I. Leontiadis,Remo Panaccione,A. Hillary Steinhart,Francis Tse,Brian G. Feagan,Waqqas Afif,Edmond-Jean Bernard,Mark Borgaonkar,Shane M. Devlin,Richard N. Fedorak,Geoffrey C. Nguyen,Robert M Penner,Laurent Peyrin-Biroulet,Walter Reinisch,Cynthia H. Seow,Richmond Sy,Laura E. Targownik,Peter Thomson,Gert Van Assche,Chadwick Williams +24 more
TL;DR: Canadian consensus guidelines for the treatment of ambulatory patients with mild to severe active UC conclude that the goal of therapy is complete remission, defined as both symptomatic and endoscopic remission without corticosteroid therapy.
References
More filters
Journal ArticleDOI
Infliximab for induction and maintenance therapy for ulcerative colitis.
Paul Rutgeerts,William J. Sandborn,Brian G. Feagan,Walter Reinisch,Allan Olson,Jewel Johanns,Suzanne Travers,Daniel Rachmilewitz,Stephen B. Hanauer,Gary R. Lichtenstein,Willem J.S. de Villiers,Daniel H. Present,Bruce E. Sands,Jean-Frederic Colombel +13 more
TL;DR: Patients with moderate-to-severe active ulcerative colitis treated with infliximab at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo.
Book
Ulcerative Colitis
TL;DR: Overall, incidence appeared to be on the rise worldwide and peak incidence occurred in the second to fourth decade of life, although a modest rise was also seen in later life, and no consistent difference was seen between the sexes.
Journal ArticleDOI
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
TL;DR: It is concluded that oral 5-ASA administered in a dosage of 4.8 g per day is effective therapy, at least in the short term, for mildly to moderately active ulcerative colitis.
Journal ArticleDOI
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.
Geert D'Haens,William J. Sandborn,Brian G. Feagan,Karel Geboes,Stephen B. Hanauer,E. Jan Irvine,Marc Lémann,Philippe Marteau,Paul Rutgeerts,Jürgen Schölmerich,Lloyd R. Sutherland +10 more
TL;DR: The results were summarized in a draft manuscript by the primary authors (G.D. and W.J. as discussed by the authors ) and discussed at the annual IOIBD meetings in 2004 and 2005.
Journal ArticleDOI
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn,Gert Van Assche,Walter Reinisch,Jean-Frederic Colombel,Geert R. D'Haens,Douglas C. Wolf,Martina Kron,Mary Beth Tighe,Andreas Lazar,Roopal Thakkar +9 more
TL;DR: Adalimumab was safe and more effective than placebo in inducing and maintaining clinical remission in patients with moderate-to-severe ulcerative colitis who did not have an adequate response to conventional therapy with steroids or immunosuppressants.